| scholarly article | Q13442814 |
| P50 | author | Ronald C. Petersen | Q56839853 |
| Leonard Petrucelli | Q61643074 | ||
| Nirubol Tosakulwong | Q83230341 | ||
| Stephen Weigand | Q88487393 | ||
| Jennifer L Whitwell | Q99637904 | ||
| P2093 | author name string | Dennis W Dickson | |
| Keith A Josephs | |||
| Joseph E Parisi | |||
| Melissa E Murray | |||
| Amanda M Liesinger | |||
| P2860 | cites work | “Mini-mental state” | Q25938989 |
| Self-propagation of pathogenic protein aggregates in neurodegenerative diseases | Q26996441 | ||
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q28131672 | ||
| TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease | Q28301503 | ||
| The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease | Q29614948 | ||
| TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q29615597 | ||
| The Clinical Dementia Rating (CDR): current version and scoring rules | Q29616280 | ||
| TDP-43 in Alzheimer's disease is not associated with clinical FTLD or Parkinsonism | Q33911422 | ||
| TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease | Q33992842 | ||
| TDP-43 is a key player in the clinical features associated with Alzheimer's disease | Q34232167 | ||
| Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry | Q34556945 | ||
| Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. | Q34601207 | ||
| Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes | Q34604146 | ||
| Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease | Q35661053 | ||
| National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach | Q35706615 | ||
| Incidence and extent of TDP-43 accumulation in aging human brain | Q35759384 | ||
| Trans-cellular propagation of Tau aggregation by fibrillar species | Q36003836 | ||
| Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease | Q36115656 | ||
| TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features | Q36217832 | ||
| Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies | Q36860214 | ||
| TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies | Q36951533 | ||
| Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity | Q37164410 | ||
| TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease | Q37179756 | ||
| Cell-to-cell transmission of non-prion protein aggregates. | Q37200740 | ||
| Stages of pTDP-43 pathology in amyotrophic lateral sclerosis | Q37202139 | ||
| A critical reappraisal of current staging of Lewy-related pathology in human brain | Q37204046 | ||
| Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. | Q37425165 | ||
| Staging TDP-43 pathology in Alzheimer's disease | Q37621617 | ||
| Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria | Q37631959 | ||
| The transcellular spread of cytosolic amyloids, prions, and prionoids | Q37671889 | ||
| Invited review: Prion-like transmission and spreading of tau pathology | Q38268519 | ||
| Prion-like properties of pathological TDP-43 aggregates from diseased brains | Q39129644 | ||
| Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology | Q47861971 | ||
| Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years | Q48835886 | ||
| TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype | Q48864196 | ||
| Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. | Q53299106 | ||
| Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease | Q57306418 | ||
| Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease | Q73789480 | ||
| P433 | issue | 4 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 571-585 | |
| P577 | publication date | 2016-01-25 | |
| P1433 | published in | Acta Neuropathologica | Q343168 |
| P1476 | title | Updated TDP-43 in Alzheimer's disease staging scheme | |
| P478 | volume | 131 |
| Q38841003 | "New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). |
| Q90248276 | A review on shared clinical and molecular mechanisms between bipolar disorder and frontotemporal dementia |
| Q90340969 | Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration |
| Q93029608 | Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43 |
| Q92286200 | Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer's Disease |
| Q89859049 | Awakening the dark side: retrotransposon activation in neurodegenerative disorders |
| Q50350613 | Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies. |
| Q48388590 | Brain tau deposition linked to systemic causes of death in normal elderly |
| Q50011514 | Can Addressing Personality Change Enhance Cognitive Functioning and Delay Development of Mild Cognitive Impairment? |
| Q92452150 | Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players |
| Q38884647 | Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. |
| Q47351811 | Detergent Insoluble Proteins and Inclusion Body-Like Structures Immunoreactive for PRKDC/DNA-PK/DNA-PKcs, FTL, NNT, and AIFM1 in the Amygdala of Cognitively Impaired Elderly Persons. |
| Q60043858 | Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer's disease and cerebrovascular disease pathologies |
| Q42617513 | Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis |
| Q94460627 | Distinct molecular patterns of TDP-43 pathology in Alzheimer's disease: relationship with clinical phenotypes |
| Q48122054 | Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy |
| Q92587499 | Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes |
| Q97523300 | Effect of A/T/N imaging biomarkers on impaired odor identification in Alzheimer's disease |
| Q57165224 | Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study |
| Q93170967 | Expression profiling of precuneus layer III cathepsin D-immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability |
| Q34546133 | Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases |
| Q93214027 | In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies |
| Q47123732 | In vivo staging of regional amyloid deposition |
| Q42503963 | Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series |
| Q39236779 | Interactions of pathological proteins in neurodegenerative diseases |
| Q92267709 | LATE to the PART-y |
| Q64385732 | Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. |
| Q97554765 | Longitudinal validity of PET-based staging of regional amyloid deposition |
| Q57464016 | Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series |
| Q34551345 | Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players |
| Q93349242 | Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease |
| Q47769597 | Neuropathological comorbidity associated with argyrophilic grain disease. |
| Q37230835 | Neuropathology of supercentenarians - four autopsy case studies |
| Q38915426 | Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi |
| Q48020146 | Pathology and hippocampal atrophy in Alzheimer's disease |
| Q40414517 | Pathomechanisms and clinical aspects of frontotemporal lobar degeneration |
| Q52730092 | Pathomechanisms of TDP-43 in neurodegeneration. |
| Q58090414 | Phosphorylated TDP-43 Staging of Primary Age-Related Tauopathy |
| Q47727180 | Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration. |
| Q90059432 | Primary age-related tauopathy in a Chinese cohort |
| Q91705222 | Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases |
| Q92381285 | Putative risk alleles for LATE-NC with hippocampal sclerosis in population-representative autopsy cohorts |
| Q47268164 | Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study |
| Q52670912 | Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC. |
| Q50211142 | Regional Overlap of Pathologies in Lewy Body Disorders |
| Q92591355 | Resistance and resilience to Alzheimer's disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort |
| Q55337947 | Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain. |
| Q48091832 | Spinal Lewy body pathology in older adults without an antemortem diagnosis of Parkinson's disease |
| Q59858789 | TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia |
| Q93013749 | TDP-43 and Limbic-Predominant Age-Related TDP-43 Encephalopathy |
| Q89476365 | TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease |
| Q38382398 | TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD. |
| Q53397720 | TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer's disease. |
| Q39331146 | TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia |
| Q90051401 | TDP-43 α-helical structure tunes liquid-liquid phase separation and function |
| Q90379423 | TDP-43: From Alzheimer's Disease to Limbic-Predominant Age-Related TDP-43 Encephalopathy |
| Q34550595 | Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). |
| Q37621005 | Tdp-43 cryptic exons are highly variable between cell types |
| Q97426059 | Testing Amyloid Cross-Toxicity in the Vertebrate Brain |
| Q46251905 | The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases |
| Q92570889 | The Missing Heritability of Sporadic Frontotemporal Dementia: New Insights from Rare Variants in Neurodegenerative Candidate Genes |
| Q64054884 | The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD |
| Q90295506 | The basis of clinicopathological heterogeneity in TDP-43 proteinopathy |
| Q91679862 | The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals |
| Q100533889 | The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies |
| Q91983577 | The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain |
| Q40966843 | Transactive DNA Binding Protein 43 Rather Than Other Misfolded Proteins in the Brain is Associated with Islet Amyloid Polypeptide in Pancreas in Aged Subjects with Diabetes Mellitus |
| Q60054668 | Uncoupling protein 4 () gene variability in neurodegenerative disorders: further evidence of association in Frontotemporal dementia |
| Q94450972 | Validation of machine learning models to detect amyloid pathologies across institutions |
| Q64236932 | Young adult-onset, very slowly progressive cognitive decline with spastic paraparesis in Alzheimer's disease with cotton wool plaques due to a novel presenilin1 G417S mutation |
| Q49808601 | mRNP assembly, axonal transport, and local translation in neurodegenerative diseases |
Search more.